ExpreS2ion publishes video presentations from Biostock Life Science Summit and Analysguiden Stora Aktiedagarna
Hørsholm, Denmark, 2 December 2024 – ExpreS2ion Biotech Holding AB’s subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that filmed company presentations in which CEO Bent Frandsen shared insights into the company’s development strategy and value creation potential are now available on the company’s website.
The first presentation was delivered at the Biostock Life Science Summit on 21 November 2024. The second took place at the Aktiespararna event Stora Aktiedagarna in Stockholm on 27 November 2024. Both presentations highlighted ExpreS2ion’s novel HER2-targeted therapeutic cancer vaccine program, ES2B-C001, and the company's progress toward key milestones.
Key topics covered include:
- The unmet medical need for HER2-positive cancer treatments and the transformative potential of ES2B-C001
- Strong preclinical data, demonstrating significant tumour growth inhibition and survival outcomes
- The company’s integrated development plan (iDP), positioning ExpreS2ion for value creation through strategic milestones, including the anticipated decision on the Phase I clinical trial application.
The presentations can be found on the Company’s investor website via the following link: https://investor.expres2ionbio.com/presentations/
Certified Adviser
Svensk Kapitalmarknadsgranskning AB